Brief: Elicera Therapeutics Q4 Oper Loss Widens To SEK 4 Mln
17/02/2023 07:27
Feb 17 (Reuters) - Elicera Therapeutics AB ELIC.ST :
* Q4 OPERATING PROFIT/LOSS TOTALED SEK -3,951,799
(-2,142,267)
Source text for Eikon: ID:nWkr5hgKsB
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Nomination Committee Proposes Margareth Jorvid As Chair Of Elicera Board
Brief: Elicera Therapeutics Carries Out Rights Issue Of About SEK 73 Mln
Sweden's Elicera Therapeutics Q1 loss narrows, reports positive clinical progress
Brief: Elicera Therapeutics Q1 Operating Loss SEK 5.1 Mln
Brief: Elicera Therapeutics Gets Notice Of Allowance For Japanease Patent